“Innovation and Entrepreneurship Collaboration Key to Economic Growth” - Dr. Abdalla Alnajjar, President of the Arab Science & Technology Foundation (ASTF)
Dubai, United Arab Emirates - Thursday, February 5th 2015 [ME NewsWire]
Dr Abdalla Alnajjar, Emirati entrepreneur and President of the Arab Science & Technology Foundation (ASTF), provided the key note speech on innovation and entrepreneurship at a Dubai Biotechnology and Research Park (DuBiotech) life sciences innovation forum. Dr Alnajjar stated that collaboration between innovation and entrepreneurship is an essential catalyst for economic growth.
DuBiotech, the free zone business park dedicated to fostering the growth of the region’s life sciences industry, brought together over 150 industry and business leaders to share insights into recent developments in the sector, as well the identification of potential barriers. How to drive the UAE’s Innovation Strategy was also discussed.
Abdalla Alnajjar said: “Innovation creates change and advancement for an industry. It disrupts the status quo, but it does not automatically translate to entrepreneurship or new business. Entrepreneurship is vital to capitalise on innovation and give life to the idea.
“As UAE businesses move towards an innovation-led economy, the combination of these two elements will be crucial in creating new businesses or business initiatives, encouraging new ideas, and driving economic growth.”
In order to capture the changing landscape of innovation in the life sciences industry, DuBiotech polled the forum attendees with several innovation themed questions. The resulting data revealed that 67 per cent of respondents consider their employer or business to be innovative, whilst 77 per cent confirm their company has a system in place to capture new ideas. Nearly half of the attendees (48 per cent) consider entrepreneurs to be the key driver for and the source of innovation in Dubai.
The survey also identified the potential barriers to the growth of innovation in Dubai; 27 per cent of respondents believe lack of funding for innovation-based research to be the most crucial barrier to the realisation of Dubai’s innovation goals, while 23 per cent see current market dynamics as hostile to the environment required for fostering innovation. Intellectual property and patent protection regulations in the region were also highlighted as being areas of concern.
Commenting on the results of the poll, Marwan Abdulaziz, Executive Director, TECOM Investments’ DuBiotech and EnPark said:
“The UAE is the most innovative nation in the GCC, but our goals are much higher than this. We are currently ranked 24th for innovation according to the World Economic Forum (WEF) Global Competitiveness Index, and have set ourselves the target of becoming one of the most innovative nations in the world through the National Innovation Strategy. The strategy requires all government agencies to invest into research and projects driving innovation.
At DuBiotech, we aim to create an innovative environment for our business partners, with purpose build commercial offices, research and lab facilities, high-level networking opportunities, and strong connections to Government and academia. Surveys like this are an excellent indicator of public perception, and can assist in refining the UAE’s approach, and educate us on positive developments and potential barriers to the UAE achieving its goals.
After looking into these snapshot results, we at DuBiotech have decided to invest in further, more comprehensive research into innovation in the life sciences industry, to assist the UAE in becoming one of the world’s most innovative nations.”
DuBiotech and TECOM Investments continue to support His Highness Sheikh Mohammed Bin Rashid Al Maktoum’s vision to transform Dubai into an innovation-driven economy. In October 2014, TECOM Investments’ introduced a strategy focused on new innovation initiatives, stimulating creativity and the development of new technologies, creating smart and sustainable infrastructure, and driving entrepreneurship and SME growth, with a combined total investment AED 4.5 billion
Ends
About DuBiotech
Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments, is a free zone business park dedicated to fostering the growth of the life sciences industry in the region. DuBiotech was established to support the Government of Dubai’s vision to transform the UAE into a knowledge-based economy and develop the region’s talent pool.
DuBiotech offers world-class infrastructure and cutting edge research and development facilities, specifically designed and built for the field of biotechnology, pharmaceutical, medical and scientific device, food and agricultural industries. The free zone can support both start-ups and international firms looking for a regional base for their Middle East or global operations. The park is central to a community that is committed to the industry’s success by bringing together business, regulators and Government in partnership.
Since its launch in 2005, DuBiotech has rapidly grown into a community of more than195 life sciences companies such as Pfizer, Merck-Serono, Amgen, Bristol-Myers Squibb, Maquet, National Reference Lab, ThermoFisher, Bayer, Mylan, Firmenich and IFF.
For further information on DuBiotech, please visit our website: www.dubiotech.ae.
Contacts
For further information:
Iain Munro, Bell Pottinger
Mobile: +971 555597389
Email: imunro@bell-pottinger.com
Permalink: http://me-newswire.net/news/13566/en
Dubai, United Arab Emirates - Thursday, February 5th 2015 [ME NewsWire]
Dr Abdalla Alnajjar, Emirati entrepreneur and President of the Arab Science & Technology Foundation (ASTF), provided the key note speech on innovation and entrepreneurship at a Dubai Biotechnology and Research Park (DuBiotech) life sciences innovation forum. Dr Alnajjar stated that collaboration between innovation and entrepreneurship is an essential catalyst for economic growth.
DuBiotech, the free zone business park dedicated to fostering the growth of the region’s life sciences industry, brought together over 150 industry and business leaders to share insights into recent developments in the sector, as well the identification of potential barriers. How to drive the UAE’s Innovation Strategy was also discussed.
Abdalla Alnajjar said: “Innovation creates change and advancement for an industry. It disrupts the status quo, but it does not automatically translate to entrepreneurship or new business. Entrepreneurship is vital to capitalise on innovation and give life to the idea.
“As UAE businesses move towards an innovation-led economy, the combination of these two elements will be crucial in creating new businesses or business initiatives, encouraging new ideas, and driving economic growth.”
In order to capture the changing landscape of innovation in the life sciences industry, DuBiotech polled the forum attendees with several innovation themed questions. The resulting data revealed that 67 per cent of respondents consider their employer or business to be innovative, whilst 77 per cent confirm their company has a system in place to capture new ideas. Nearly half of the attendees (48 per cent) consider entrepreneurs to be the key driver for and the source of innovation in Dubai.
The survey also identified the potential barriers to the growth of innovation in Dubai; 27 per cent of respondents believe lack of funding for innovation-based research to be the most crucial barrier to the realisation of Dubai’s innovation goals, while 23 per cent see current market dynamics as hostile to the environment required for fostering innovation. Intellectual property and patent protection regulations in the region were also highlighted as being areas of concern.
Commenting on the results of the poll, Marwan Abdulaziz, Executive Director, TECOM Investments’ DuBiotech and EnPark said:
“The UAE is the most innovative nation in the GCC, but our goals are much higher than this. We are currently ranked 24th for innovation according to the World Economic Forum (WEF) Global Competitiveness Index, and have set ourselves the target of becoming one of the most innovative nations in the world through the National Innovation Strategy. The strategy requires all government agencies to invest into research and projects driving innovation.
At DuBiotech, we aim to create an innovative environment for our business partners, with purpose build commercial offices, research and lab facilities, high-level networking opportunities, and strong connections to Government and academia. Surveys like this are an excellent indicator of public perception, and can assist in refining the UAE’s approach, and educate us on positive developments and potential barriers to the UAE achieving its goals.
After looking into these snapshot results, we at DuBiotech have decided to invest in further, more comprehensive research into innovation in the life sciences industry, to assist the UAE in becoming one of the world’s most innovative nations.”
DuBiotech and TECOM Investments continue to support His Highness Sheikh Mohammed Bin Rashid Al Maktoum’s vision to transform Dubai into an innovation-driven economy. In October 2014, TECOM Investments’ introduced a strategy focused on new innovation initiatives, stimulating creativity and the development of new technologies, creating smart and sustainable infrastructure, and driving entrepreneurship and SME growth, with a combined total investment AED 4.5 billion
Ends
About DuBiotech
Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments, is a free zone business park dedicated to fostering the growth of the life sciences industry in the region. DuBiotech was established to support the Government of Dubai’s vision to transform the UAE into a knowledge-based economy and develop the region’s talent pool.
DuBiotech offers world-class infrastructure and cutting edge research and development facilities, specifically designed and built for the field of biotechnology, pharmaceutical, medical and scientific device, food and agricultural industries. The free zone can support both start-ups and international firms looking for a regional base for their Middle East or global operations. The park is central to a community that is committed to the industry’s success by bringing together business, regulators and Government in partnership.
Since its launch in 2005, DuBiotech has rapidly grown into a community of more than195 life sciences companies such as Pfizer, Merck-Serono, Amgen, Bristol-Myers Squibb, Maquet, National Reference Lab, ThermoFisher, Bayer, Mylan, Firmenich and IFF.
For further information on DuBiotech, please visit our website: www.dubiotech.ae.
Contacts
For further information:
Iain Munro, Bell Pottinger
Mobile: +971 555597389
Email: imunro@bell-pottinger.com
Permalink: http://me-newswire.net/news/13566/en
No comments:
Post a Comment